Current and historical daily PE Ratio for Rain Oncology Inc (
) from 2021 to Jun 09 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Rain Oncology stock (RAIN) PE ratio as of Jun 09 2024 is 0.
More Details
Rain Oncology Inc (RAIN) PE Ratio (TTM) Chart
Rain Oncology Inc (RAIN) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 696
- 1
- 2
- 3
- 4
- 5
- 6
- 8
| Rain Oncology PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-09 | At Loss | 2023-11-21 | At Loss |
| 2024-01-26 | At Loss | 2023-11-20 | At Loss |
| 2024-01-25 | At Loss | 2023-11-17 | At Loss |
| 2024-01-24 | At Loss | 2023-11-16 | At Loss |
| 2024-01-23 | At Loss | 2023-11-15 | At Loss |
| 2024-01-22 | At Loss | 2023-11-14 | At Loss |
| 2024-01-19 | At Loss | 2023-11-13 | At Loss |
| 2024-01-18 | At Loss | 2023-11-10 | At Loss |
| 2024-01-17 | At Loss | 2023-11-09 | At Loss |
| 2024-01-16 | At Loss | 2023-11-08 | At Loss |
| 2024-01-12 | At Loss | 2023-11-07 | At Loss |
| 2024-01-11 | At Loss | 2023-11-06 | At Loss |
| 2024-01-10 | At Loss | 2023-11-03 | At Loss |
| 2024-01-09 | At Loss | 2023-11-02 | At Loss |
| 2024-01-08 | At Loss | 2023-11-01 | At Loss |
| 2024-01-05 | At Loss | 2023-10-31 | At Loss |
| 2024-01-04 | At Loss | 2023-10-30 | At Loss |
| 2024-01-03 | At Loss | 2023-10-27 | At Loss |
| 2024-01-02 | At Loss | 2023-10-26 | At Loss |
| 2023-12-29 | At Loss | 2023-10-25 | At Loss |
| 2023-12-28 | At Loss | 2023-10-24 | At Loss |
| 2023-12-27 | At Loss | 2023-10-23 | At Loss |
| 2023-12-26 | At Loss | 2023-10-20 | At Loss |
| 2023-12-22 | At Loss | 2023-10-19 | At Loss |
| 2023-12-21 | At Loss | 2023-10-18 | At Loss |
| 2023-12-20 | At Loss | 2023-10-17 | At Loss |
| 2023-12-19 | At Loss | 2023-10-16 | At Loss |
| 2023-12-18 | At Loss | 2023-10-13 | At Loss |
| 2023-12-15 | At Loss | 2023-10-12 | At Loss |
| 2023-12-14 | At Loss | 2023-10-11 | At Loss |
| 2023-12-13 | At Loss | 2023-10-10 | At Loss |
| 2023-12-12 | At Loss | 2023-10-09 | At Loss |
| 2023-12-11 | At Loss | 2023-10-06 | At Loss |
| 2023-12-08 | At Loss | 2023-10-05 | At Loss |
| 2023-12-07 | At Loss | 2023-10-04 | At Loss |
| 2023-12-06 | At Loss | 2023-10-03 | At Loss |
| 2023-12-05 | At Loss | 2023-10-02 | At Loss |
| 2023-12-04 | At Loss | 2023-09-29 | At Loss |
| 2023-12-01 | At Loss | 2023-09-28 | At Loss |
| 2023-11-30 | At Loss | 2023-09-27 | At Loss |
| 2023-11-29 | At Loss | 2023-09-26 | At Loss |
| 2023-11-28 | At Loss | 2023-09-25 | At Loss |
| 2023-11-27 | At Loss | 2023-09-22 | At Loss |
| 2023-11-24 | At Loss | 2023-09-21 | At Loss |
| 2023-11-22 | At Loss | 2023-09-20 | At Loss |
Rain Oncology Inc (RAIN) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Rain Oncology Inc
NAICS : 541714
SIC : 2834
ISIN : US75082Q1058
Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers